Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	21.12	-75.37	-58.98	-66.05	-53.16	-35.24
Depreciation & Amortization	0.12	0.11	0.04	0.2	0.26	0.55
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.53
Loss (Gain) on Equity Investments	0.14	0.1	0.01	0.05	0.05	-
Stock-Based Compensation	8.2	5.39	5.55	7.71	4.89	2.81
Other Operating Activities	-97.03	3.99	5.65	3.1	0.79	0.83
Change in Accounts Payable	3.82	1.39	3.08	1.3	-0.2	-1.49
Change in Income Taxes	-	-	-	-	-	-0
Change in Other Net Operating Assets	3.2	-4.41	1.67	-2.98	-6.88	0.22
Operating Cash Flow	-64.05	-68.79	-42.97	-56.67	-54.25	-31.79
Investment in Securities	-	-	-	-	-	-0.9
Investing Cash Flow	-	-	-	-	-	-0.9
Long-Term Debt Issued	-	-	30	10	10	0.9
Long-Term Debt Repaid	-	-0	-10.23	-12.32	-3.69	-0.26
Net Debt Issued (Repaid)	0.19	-0	19.77	-2.32	6.31	0.64
Issuance of Common Stock	24.18	60.33	30.02	62.51	49.9	36.57
Other Financing Activities	-	-	-0.82	-0.6	-0.01	-
Financing Cash Flow	24.37	60.33	48.97	59.59	56.19	37.21
Net Cash Flow	-39.67	-8.46	6	2.92	1.94	4.52
Free Cash Flow	-64.05	-68.79	-42.97	-56.67	-54.25	-31.79
Free Cash Flow Per Share	-2.51	-3.71	-3.44	-5.34	-7.11	-8.76
Cash Interest Paid	-	0.48	1.16	1.56	0.05	0.91
Levered Free Cash Flow	-35.91	-44.3	-24.26	-32.53	-35.62	-17.11
Unlevered Free Cash Flow	-35.74	-42.33	-22.68	-31.6	-35.03	-16.01
Change in Working Capital	3.41	-3.02	4.75	-1.68	-7.08	-1.27

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q